Washington University in St. Louis and informatics firm BostonGene announced Thursday an expanded collaboration on profiling renal cell carcinoma (RCC), a type of kidney cancer, and its tumor microenvironment.
A research collaboration between biomedical software startup BostonGene and Weill Cornell Medicine has found that the tumor microenvironment influences the prognosis of patients with diffuse large B-cell lymphoma (DLBCL), suggesting that genomics alone may not provide a complete picture of a patient’s disease trajectory.
BostonGene today announced a partnership with the National Institutes of Health to offer molecular profiling and therapy recommendations in a cancer study.
Biomedical software startup BostonGene is refreshed and ready to take on the world of cancer treatment.
BostonGene plans to commercialize its technology for selecting the best therapies for cancer patients.